Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Down 8.3% in September

Innate Pharma S.A. (NASDAQ:IPHA) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 59,700 shares, a decrease of 8.3% from the August 31st total of 65,100 shares. Based on an average trading volume of 6,600 shares, the short-interest ratio is presently 9.0 days.

Innate Pharma Stock Up 4.1 %

IPHA stock traded up $0.09 during trading on Monday, reaching $2.29. 24,592 shares of the company were exchanged, compared to its average volume of 9,027. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.92 and a quick ratio of 3.73. The company has a 50-day moving average of $2.23 and a two-hundred day moving average of $2.37. Innate Pharma has a twelve month low of $1.81 and a twelve month high of $3.15.

Analyst Ratings Changes

Several brokerages recently issued reports on IPHA. Evercore ISI upgraded Innate Pharma to a “strong-buy” rating in a research note on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $11.50 target price on shares of Innate Pharma in a research report on Friday, September 13th.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.